

Sundar Jagannath

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8586330/publications.pdf>

Version: 2024-02-01

286
papers

23,953
citations

41323

49
h-index

8156

148
g-index

292
all docs

292
docs citations

292
times ranked

21879
citing authors

#	ARTICLE	IF	CITATIONS
1	Ciltacabtagene Autoleucl, an Anti-BCMA B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. <i>Journal of Clinical Oncology</i> , 2023, 41, 1265-1274.	0.8	160
2	Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 129-132.	0.2	1
3	Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 326-335.	0.2	27
4	Comparative Efficacy of Ciltacabtagene Autoleucl in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. <i>Clinical Drug Investigation</i> , 2022, 42, 29-41.	1.1	16
5	Targeting Nuclear Export Proteins in Multiple Myeloma Therapy. <i>BioDrugs</i> , 2022, 36, 13-25.	2.2	5
6	Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e526-e531.	0.2	10
7	Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucl in CARTITUDE studies. <i>Blood Cancer Journal</i> , 2022, 12, 32.	2.8	73
8	Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients. <i>Cancer Cell</i> , 2022, 40, 441-443.	7.7	29
9	Comparative effectiveness of ciltacabtagene autoleucl in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma. <i>EJHaem</i> , 2022, 3, 97-108.	0.4	13
10	Healthcare Costs of Multiple Myeloma Patients with Four or More Prior Lines of Therapy, Including Triple-Class Exposure in the United States. <i>Oncology and Therapy</i> , 2022, 10, 411-420.	1.0	2
11	Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucl in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 690-701.	0.2	8
12	Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. <i>New England Journal of Medicine</i> , 2022, 387, 132-147.	13.9	173
13	A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma. <i>JCO Precision Oncology</i> , 2022, , .	1.5	7
14	Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	16
15	Phase 1b/2 study of ciltacabtagene autoleucl, a BCMA-directed CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): Two years post-LPI. <i>Journal of Clinical Oncology</i> , 2022, 40, 8028-8028.	0.8	9
16	Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect MM Registry. <i>British Journal of Haematology</i> , 2021, 193, 93-100.	1.2	4
17	Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. <i>American Journal of Hematology</i> , 2021, 96, E5-E8.	2.0	20
18	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. <i>Cancer</i> , 2021, 127, 82-92.	2.0	15

#	ARTICLE	IF	CITATIONS
19	A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma. Expert Review of Hematology, 2021, 14, 31-45.	1.0	7
20	Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class refractory multiple myeloma. EJHaem, 2021, 2, 48-55.	0.4	8
21	Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma. Therapeutic Advances in Hematology, 2021, 12, 204062072098707.	1.1	10
22	Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma. Blood Advances, 2021, 5, 367-376.	2.5	8
23	Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. Cancer, 2021, 127, 1816-1826.	2.0	9
24	Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. Journal of Hematology and Oncology, 2021, 14, 59.	6.9	11
25	Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma.. Journal of Clinical Oncology, 2021, 39, 8024-8024.	0.8	2
26	Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e470-e476.	0.2	12
27	Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. American Journal of Hematology, 2021, 96, 708-718.	2.0	16
28	Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study.. Journal of Clinical Oncology, 2021, 39, 8036-8036.	0.8	3
29	Comparison of outcomes with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 versus real-world standard of care (RW SOC) for patients (pts) with triple-class exposed relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology, 2021, 39, 8045-8045.	0.8	6
30	Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1.. Journal of Clinical Oncology, 2021, 39, 8005-8005.	0.8	23
31	KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Blood Cancer Journal, 2021, 11, 116.	2.8	44
32	Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e975-e984.	0.2	5
33	Selinexor for the treatment of patients with previously treated multiple myeloma. Expert Review of Hematology, 2021, 14, 697-706.	1.0	6
34	Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone. American Journal of Hematology, 2021, 96, E383-E386.	2.0	7
35	Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. American Journal of Hematology, 2021, 96, 1120-1130.	2.0	15
36	Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet, The, 2021, 398, 314-324.	6.3	711

#	ARTICLE	IF	CITATIONS
37	Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	12
38	Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. <i>Cancer Cell</i> , 2021, 39, 1028-1030.	7.7	176
39	Bispecific Antibodies in Multiple Myeloma: Present and Future. <i>Blood Cancer Discovery</i> , 2021, 2, 423-433.	2.6	43
40	Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. <i>Lancet Haematology</i> , 2021, 8, e794-e807.	2.2	15
41	Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. <i>Blood Cancer Journal</i> , 2021, 11, 10.	2.8	53
42	Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. <i>Cancer Cell</i> , 2021, 39, 1442-1444.	7.7	62
43	Healthcare Costs Incurred by Patients with Multiple Myeloma Following Triple Class Exposure (TCE) in the US. <i>Oncology and Therapy</i> , 2021, 9, 659-669.	1.0	6
44	The Safety and Efficacy of Radiation Therapy with Concurrent Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin-Based Systemic Therapy for Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, , .	0.2	3
45	Digital Health for Patients With Multiple Myeloma: An Unmet Need. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 1096-1105.	1.0	12
46	Efficacy and Safety of Ciltacabtagene Autoleucl in Patients With Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 Subgroup Analysis. <i>Blood</i> , 2021, 138, 3938-3938.	0.6	7
47	Ciltacabtagene Autoleucl for Triple-Class Exposed Multiple Myeloma: Adjusted Comparisons of CARTITUDE-1 Patient Outcomes Versus Therapies from Real-World Clinical Practice from the LocoMMotion Prospective Study. <i>Blood</i> , 2021, 138, 550-550.	0.6	9
48	Anakinra Targeting Cytokine Release Syndrome Associated with Chimeric Antigen Receptor T-Cell Therapies. <i>Blood</i> , 2021, 138, 2812-2812.	0.6	5
49	Title: Genomic and Systemic Metabolism Differences Associated with Racial Disparities in Multiple Myeloma. <i>Blood</i> , 2021, 138, 1601-1601.	0.6	0
50	Cost per Responder Analysis to Assess the Value of CAR-T Therapy for Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 4961-4961.	0.6	0
51	Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 651-651.	0.6	30
52	Clinical Outcomes and Treatment Strategies for Relapsed/Refractory Myeloma Patients after Relapse on BCMA-Targeted CAR T. <i>Blood</i> , 2021, 138, 2704-2704.	0.6	6
53	Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry. <i>Cancers</i> , 2021, 13, 5996.	1.7	8
54	Baseline Correlates of Complete Response to Idecabtagene Vicleucl (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial. <i>Blood</i> , 2021, 138, 1739-1739.	0.6	6

#	ARTICLE	IF	CITATIONS
55	Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome with REGN5458, a BCMAxCD3 Bispecific Monoclonal Antibody, in a Phase 1/2 First-in-Human Study in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2021, 138, 160-160.	0.6	31
56	Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 548-548.	0.6	45
57	Updated Results from CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 549-549.	0.6	36
58	Clinical Outcomes of Relapsed/Refractory Multiple Myeloma Patients Following Treatment with Bispecific Antibodies (BiAbs). <i>Blood</i> , 2021, 138, 821-821.	0.6	2
59	Large-Scale Mass Cytometry Reveals Significant Activation of Innate and Adaptive Immunity in Bone Marrow Tumor Microenvironment of Ibrdomide-Treated Myeloma Patients. <i>Blood</i> , 2021, 138, 730-730.	0.6	4
60	Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications. <i>Science Advances</i> , 2021, 7, eabg9551.	4.7	49
61	Characterization and Management of Oral and Dermatological Toxicities in Patients Receiving the CD3 X GPRC5D Bispecific Antibody Talquetamab (JNJ-64407564) for the Treatment of Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 1658-1658.	0.6	9
62	Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd). <i>Blood</i> , 2021, 138, 1634-1634.	0.6	1
63	Ibrdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial. <i>Blood</i> , 2021, 138, 162-162.	0.6	9
64	Total Car-T Cost of Care Beyond the Price of Car-T Cell Therapy in Patients with Multiple Myeloma. <i>Blood</i> , 2021, 138, 4964-4964.	0.6	4
65	Triple MAPK Inhibition Salvaged a Relapsed Post BCMA CAR-T Cell Therapy in Multiple Myeloma Patient with BRAF V600E Dominant Clone. <i>Blood</i> , 2021, 138, 4720-4720.	0.6	0
66	Single-Cell Profiling Reveals Contribution of Tumor Extrinsic and Intrinsic Factors to BCMA-Targeted CAR-T Cell Efficacy in Multiple Myeloma. <i>Blood</i> , 2021, 138, 326-326.	0.6	5
67	Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study. <i>Blood</i> , 2021, 138, 3793-3793.	0.6	6
68	Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. <i>Nature Medicine</i> , 2021, 27, 2099-2103.	15.2	92
69	Connect MM Registry as a national reference for United States multiple myeloma patients. <i>Cancer Medicine</i> , 2020, 9, 35-42.	1.3	14
70	Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 272-276.	0.2	16
71	Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 450-464.	3.2	62
72	Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m^2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m^2 . <i>American Journal of Hematology</i> , 2020, 95, E51-E54.	2.0	0

#	ARTICLE	IF	CITATIONS
73	Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma. <i>Annals of Hematology</i> , 2020, 100, 3057-3060.	0.8	2
74	Where you live can impact your cancer risk: a look at multiple myeloma in New York City. <i>Annals of Epidemiology</i> , 2020, 48, 43-50.e4.	0.9	9
75	A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. <i>Journal of Hematology and Oncology</i> , 2020, 13, 94.	6.9	107
76	COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. <i>Blood Cancer Discovery</i> , 2020, 1, 234-243.	2.6	46
77	Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review. <i>Expert Review of Hematology</i> , 2020, 13, 943-958.	1.0	16
78	Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis. <i>Cancer</i> , 2020, 126, 4332-4340.	2.0	18
79	An inflammatory cytokine signature predicts COVID-19 severity and survival. <i>Nature Medicine</i> , 2020, 26, 1636-1643.	15.2	1,860
80	A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2208-2215.	0.6	7
81	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2020, 396, 1563-1573.	6.3	188
82	Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e734-e751.	0.2	2
83	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. <i>Leukemia</i> , 2020, 34, 2430-2440.	3.3	54
84	Increased Muscle CXCR4 Expression in the Setting of Rare Muscle-invasive Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e341-e344.	0.2	2
85	Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 351-357.	0.2	23
86	Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 632-636.e1.	0.2	31
87	Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis. <i>Blood</i> , 2020, 136, 16-17.	0.6	18
88	Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study. <i>Blood</i> , 2020, 136, 26-27.	0.6	32
89	CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 22-25.	0.6	63
90	Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel in the Phase 1b/2 CARTITUDE-1 Study. <i>Blood</i> , 2020, 136, 45-46.	0.6	9

#	ARTICLE	IF	CITATIONS
91	Health-Related Quality of Life in the Cartitude-1 Study of Ciltacabtagene Autoleucl for Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 41-42.	0.6	8
92	Patient Expectations and Perceptions of Treatment in CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucl in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 13-15.	0.6	5
93	First Results of Iberdomide (IBER; CC-220) in Combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 16-17.	0.6	28
94	REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2020, 136, 41-42.	0.6	48
95	Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes. <i>Blood</i> , 2020, 136, 25-26.	0.6	63
96	Idecabtagene vicleucl (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8503-8503.	0.8	93
97	Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8505-8505.	0.8	66
98	KarMMa-RW: A study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMa.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8525-8525.	0.8	12
99	A phase Ib study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/ refractory multiple myeloma (RRMM): Preliminary results.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8539-8539.	0.8	19
100	Treatment patterns in multiple myeloma: Real-world experience of the triple-class exposed (TCE) patient.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20543-e20543.	0.8	1
101	Medical resource utilization among multiple myeloma (MM) patients who were triple-exposed to a proteasome inhibitor, an immunomodulatory agent, and daratumumab.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20539-e20539.	0.8	0
102	Patient characteristics and treatment patterns in relapsed/refractory multiple myeloma patients after exposure to a proteasome inhibitor, an immunomodulatory agent and daratumumab.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20540-e20540.	0.8	1
103	Quality-of-life (QOL) analyses in patients with multiple myeloma: Results from the selinexor (KPT-330) treatment of refractory myeloma (STORM) phase IIb study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20522-e20522.	0.8	2
104	Preclinical and Translational Support for Clinical Development of Iberdomide in Combination with Proteasome Inhibitors: Mechanism of Synergy in Clinical Trial CC-220-MM-001. <i>Blood</i> , 2020, 136, 8-9.	0.6	4
105	Pilot Trial of the My Hematology Oncology Patient Experience (MyHOPEâ„¢) for Multiple Myeloma (MM) Digital Solution in Patients with MM. <i>Blood</i> , 2020, 136, 3-4.	0.6	1
106	Effect of Intravenous Immunoglobulin on Infections in Multiple Myeloma (MM) Patients Receiving Daratumumab. <i>Blood</i> , 2020, 136, 6-7.	0.6	8
107	Preclinical and Translational Data Support Development of Iberdomide in Combination with CD38- and SLAMF7-Directed Monoclonal Antibodies: Evidence for Rational Combinations. <i>Blood</i> , 2020, 136, 9-10.	0.6	3
108	Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study. <i>Blood</i> , 2020, 136, 48-50.	0.6	0

#	ARTICLE	IF	CITATIONS
109	28-Day Metronomic Therapy for Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 13-13.	0.6	0
110	Peripheral Neuropathy Symptoms, Pain and Functioning in Relapsed or Refractory Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone. <i>Blood</i> , 2020, 136, 39-41.	0.6	1
111	SOHO State of the Art Updates and Next Questions: T-Cellâ€Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptorâ€Modified T Cells and Bispecific T-Cellâ€Engaging Agents. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 537-544.	0.2	18
112	Oral Selinexorâ€Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 381, 727-738.	13.9	460
113	Monoclonal Gammopathy May Be of Unpredictable Significance. <i>JAMA Oncology</i> , 2019, 5, 1302.	3.4	3
114	Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 380, 1726-1737.	13.9	1,130
115	Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 372-380.	0.2	66
116	Frequency of and Associations Amongst Baseline Cytogenetics in Patients With Newly Diagnosed Multiple Myeloma in the ConnectÂ® MM Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e75.	0.2	1
117	Real world vs. clinical trial outcomes of triple class refractory penta-exposed multiple myeloma (MM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e115-e116.	0.2	2
118	Effect of Age on the Safety and Efficacy of Selinexor in Patients with Relapsed Refractory Multiple Myeloma: A Post-hoc Analysis of the STORM Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e117-e118.	0.2	1
119	Improvements in Renal Function with Selinexor in Relapsed/Refractory Multiple Myeloma: Post-hoc Analyses from the STORM Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e118-e119.	0.2	2
120	A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CDâ€56-positive Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 29-34.	0.2	53
121	Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM). <i>Blood</i> , 2019, 134, 577-577.	0.6	78
122	A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM). <i>Blood</i> , 2019, 134, 3116-3116.	0.6	23
123	Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220). <i>Blood</i> , 2019, 134, 3119-3119.	0.6	17
124	Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the ConnectÂ® MM Registry. <i>Blood</i> , 2019, 134, 3129-3129.	0.6	2
125	Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2019, 134, 3176-3176.	0.6	31
126	Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R MM), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell Subset. <i>Blood</i> , 2019, 134, 928-928.	0.6	23

#	ARTICLE	IF	CITATIONS
127	Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM). Blood, 2019, 134, 140-140.	0.6	22
128	Outcomes in Multiple Myeloma Patients Progressing on Lenalidomide Maintenance. Blood, 2019, 134, 1779-1779.	0.6	1
129	Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy. Blood, 2019, 134, 1854-1854.	0.6	5
130	Overall survival (OS) with oral selinexor plus low dose dexamethasone (Sd) in patients with triple class refractory-multiple myeloma (TCR-MM).. Journal of Clinical Oncology, 2019, 37, 8014-8014.	0.8	8
131	Racial and insurance disparities in multiple myeloma management in a referral center.. Journal of Clinical Oncology, 2019, 37, e18140-e18140.	0.8	0
132	Are two sites better than one?: Sites of care and quality of myeloma treatment.. Journal of Clinical Oncology, 2019, 37, e18159-e18159.	0.8	0
133	Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the ConnectA® MM Registry. Blood, 2019, 134, 1843-1843.	0.6	0
134	A Machine Learning Approach Identifies a 30-Gene Model That Predicts Sensitivity to Selinexor in Multiple Myeloma. Blood, 2019, 134, 3101-3101.	0.6	2
135	Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. British Journal of Haematology, 2018, 180, 821-830.	1.2	32
136	A phase II trial of TBL-12 sea cucumber extract in patients with untreated asymptomatic myeloma. British Journal of Haematology, 2018, 180, 296-298.	1.2	7
137	Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach. JCO Precision Oncology, 2018, 2018, 1-17.	1.5	20
138	Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. Journal of Clinical Oncology, 2018, 36, 859-866.	0.8	140
139	Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2018, 36, 812-818.	0.8	85
140	Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. Cancer, 2018, 124, 4342-4349.	2.0	29
141	Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies. Frontiers in Immunology, 2018, 9, 2616.	2.2	44
142	Society of Hematologic Oncology State of the Art Update and Next Questions: Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 693-702.	0.2	5
143	Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. Blood Advances, 2018, 2, 1470-1479.	2.5	31
144	Elotuzumab monotherapy in patients with smoldering multiple myeloma: a phase 2 study. British Journal of Haematology, 2018, 182, 495-503.	1.2	30

#	ARTICLE	IF	CITATIONS
145	Heterogeneity of Second-Line Treatment for Patients With Multiple Myeloma in the Connect MM Registry (2010-2016). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 480-485.e3.	0.2	27
146	Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry. <i>Clinical Therapeutics</i> , 2018, 40, 1193-1202.e1.	1.1	10
147	E2F1 Is a Biomarker of Selinexor Resistance in Relapsed/Refractory Multiple Myeloma Patients. <i>Blood</i> , 2018, 132, 3216-3216.	0.6	6
148	Increased HLA-E Expression Correlates with Early Relapse in Multiple Myeloma. <i>Blood</i> , 2018, 132, 59-59.	0.6	4
149	bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8007-8007.	0.8	50
150	A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8021-8021.	0.8	19
151	Early MRD negativity to predict deepening myeloma response in relapsed/refractory multiple myeloma (RRMM) patients treated with bb2121 anti-BCMA CAR T cells.. <i>Journal of Clinical Oncology</i> , 2018, 36, 8024-8024.	0.8	7
152	Association of high baseline ferritin with tocilizumab administration for CRS in relapsed/refractory multiple myeloma patients treated with bb2121 anti-BCMA CAR T cells.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15062-e15062.	0.8	0
153	Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Initial Data from a Phase 2, Non-Comparative Study. <i>Blood</i> , 2018, 132, 1991-1991.	0.6	0
154	MAGE-A3 Promotes Chemotherapy Resistance and Proliferation in Multiple Myeloma through Regulation of BIM and p21Cip1. <i>Blood</i> , 2018, 132, 4464-4464.	0.6	0
155	Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting. <i>Blood</i> , 2018, 132, 3253-3253.	0.6	0
156	Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2017, 23, 3307-3315.	3.2	203
157	Population Pharmacokinetics and Exposureâ€“Response Relationship of Carfilzomib in Patients With Multiple Myeloma. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 663-677.	1.0	10
158	Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 555-562.	0.2	28
159	A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. <i>Blood Advances</i> , 2017, 1, 1575-1583.	2.5	39
160	First-in-human multicenter study of bb2121 anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: Updated results.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3010-3010.	0.8	76
161	Impact of t(11;14) on outcomes in African American (AA) and non-AA (NAA) patients (Pts) with newly diagnosed multiple myeloma (NDMM): Connect MM registry.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8023-8023.	0.8	3
162	Impact of post-autologous stem cell transplant (ASCT) maintenance therapy on outcomes in patients (Pts) with newly diagnosed multiple myeloma (NDMM) using the large prospective community-based Connect MM registry.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8040-8040.	0.8	1

#	ARTICLE	IF	CITATIONS
163	Treatment outcomes and healthcare resource utilization (HRU) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) with lenalidomide (LEN) only or no maintenance: Connect MM registry.. Journal of Clinical Oncology, 2017, 35, e19527-e19527.	0.8	0
164	The effect of novel therapies in high-molecular-risk multiple myeloma. Clinical Advances in Hematology and Oncology, 2017, 15, 870-879.	0.3	10
165	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. , 2016, 4, 90.		17
166	Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood, 2016, 127, 2561-2568.	0.6	139
167	The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution. Cancer Medicine, 2016, 5, 500-505.	1.3	5
168	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncology, The, 2016, 17, e328-e346.	5.1	1,866
169	VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 329-334.e1.	0.2	26
170	Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma. Cancer Research, 2016, 76, 1225-1236.	0.4	25
171	Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma. Leukemia and Lymphoma, 2016, 57, 2510-2515.	0.6	18
172	Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma. Expert Review of Hematology, 2016, 9, 91-105.	1.0	7
173	Molecular Predictors of Outcome and Drug Response in Multiple Myeloma: An Interim Analysis of the MmrF CoMMpass Study. Blood, 2016, 128, 194-194.	0.6	12
174	MAGE-a Mediate Resistance to Chemotherapy in Multiple Myeloma through Regulation of Bcl-2 Proteins. Blood, 2016, 128, 3277-3277.	0.6	3
175	Phase 1 Study of Elotuzumab in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma. Blood, 2016, 128, 3448-3448.	0.6	1
176	Indatuximab Ravtansine (BT062) in Combination with Low-Dose Dexamethasone and Lenalidomide or Pomalidomide: Clinical Activity in Patients with Relapsed / Refractory Multiple Myeloma. Blood, 2016, 128, 4486-4486.	0.6	49
177	Treatment Patterns from 2009 to 2015 in Patients with Newly Diagnosed Multiple Myeloma in the United States: A Report from the ConnectÂ® MM Registry. Blood, 2016, 128, 4489-4489.	0.6	6
178	A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma. Blood, 2016, 128, 4520-4520.	0.6	3
179	Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study. Blood, 2016, 128, 491-491.	0.6	21
180	Network Modeling Reveals CDC42BPA and CLEC11A As Novel Driver Genes of t(4; 14) Multiple Myeloma. Blood, 2016, 128, 802-802.	0.6	1

#	ARTICLE	IF	CITATIONS
181	KEYNOTE-185: a randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM).. Journal of Clinical Oncology, 2016, 34, TPS8069-TPS8069.	0.8	4
182	KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM).. Journal of Clinical Oncology, 2016, 34, TPS8070-TPS8070.	0.8	5
183	Integrative Network Analysis of Newly Diagnosed Multiple Myeloma Identifies a Novel RNA-Seq Based High Riskgene Signature. Blood, 2016, 128, 3285-3285.	0.6	1
184	Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study. Blood, 2016, 128, 4414-4414.	0.6	0
185	Aberrant a-to-I RNA Editing and Prognostic Impact of Adar in Multiple Myeloma Patients with 1q Amplification. Blood, 2016, 128, 357-357.	0.6	0
186	Mutation Burden in Multiple Myeloma Is Captured By Gene Expression Profiles. Blood, 2016, 128, 4450-4450.	0.6	0
187	Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 680-686.	0.2	6
188	A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research, 2015, 21, 4055-4061.	3.2	154
189	Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma. Leukemia and Lymphoma, 2015, 56, 2959-2961.	0.6	2
190	Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1bâ€²2 dose-escalation study. Lancet Haematology,the, 2015, 2, e516-e527.	2.2	140
191	Serum Free Light Chain Assessment Early After Stem Cell Transplantation as a Prognostic Factor in Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 541-545.	0.2	6
192	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, BloodAnd Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2015, 21, 2039-2051.	2.0	146
193	A Comparison of the Outcomes of Early Versus Delayed Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Novel Therapies. Blood, 2015, 126, 1993-1993.	0.6	1
194	Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib. Blood, 2015, 126, 3051-3051.	0.6	2
195	Flow Cytometry Based Detection of MRD in Bone Marrow of Patients with Multiple Myeloma: A Comparison Between Fluorescent-Based Cytometry Versus Cytof. Blood, 2015, 126, 4195-4195.	0.6	2
196	A Phase II Study of Panobinostat with Lenalidomide and Weekly Dexamethasone in Myeloma. Blood, 2015, 126, 4226-4226.	0.6	14
197	Identification of Initiating Trunk Mutations and Distinct Molecular Subtypes: An Interim Analysis of the Mmrf Compass Study. Blood, 2015, 126, 722-722.	0.6	4
198	A phase II study of panobinostat with lenalidomide and weekly dexamethasone in myeloma.. Journal of Clinical Oncology, 2015, 33, 8528-8528.	0.8	3

#	ARTICLE	IF	CITATIONS
199	Patient-Specific Mutation-Derived Tumor Antigens As Targets for Cancer Immunotherapy in Multiple Myeloma. <i>Blood</i> , 2015, 126, 1851-1851.	0.6	0
200	Progression-Free Survival in Third-Line Treatment of Relapsed/Refractory Multiple Myeloma Among Patients with Who Have Received Prior Bortezomib and Immunomodulatory Drugs. <i>Blood</i> , 2015, 126, 3311-3311.	0.6	0
201	Asymptomatic Monoclonal Gammopathies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S78-S86.	0.2	6
202	A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. <i>Blood</i> , 2014, 123, 1461-1469.	0.6	174
203	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology</i> , The, 2014, 15, e538-e548.	5.1	3,343
204	Identifying Professional Education Gaps and Barriers in Multiple Myeloma Patient Care: Findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 356-369.	0.2	7
205	State of the art imaging of multiple myeloma: Comparative review of FDG PET/CT imaging in various clinical settings. <i>European Journal of Radiology</i> , 2014, 83, 2203-2223.	1.2	78
206	Adverse drug reaction: pomalidomide-induced liver injury. <i>Lancet</i> , The, 2014, 383, 2125-2126.	6.3	15
207	Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. <i>Haematologica</i> , 2014, 99, e162-e164.	1.7	39
208	Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. <i>Blood</i> , 2014, 123, 1826-1832.	0.6	327
209	Pharmacokinetics and Safety of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Various Levels of Renal Function: Results of a Phase 1b Study. <i>Blood</i> , 2014, 124, 2119-2119.	0.6	2
210	Final Results for the 1703 Phase 1b/2 Study of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 302-302.	0.6	13
211	Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study. <i>Blood</i> , 2014, 124, 303-303.	0.6	7
212	Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results. <i>Blood</i> , 2014, 124, 31-31.	0.6	11
213	Weighted Gene Co-Expression Network Analysis (WGCNA) Identifies Highly Proliferative Myeloma Subgroup Responsive to CDK4/ARK5 Inhibition. <i>Blood</i> , 2014, 124, 3445-3445.	0.6	9
214	A Phase II, Single-Center, Open-Label Study of Oral Panobinostat in Combination with Lenalidomide and Weekly Dexamethasone in Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 3486-3486.	0.6	3
215	Indatuximab Ravtansine (BT062) in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Clinical Activity in Patients Already Exposed to Lenalidomide and Bortezomib. <i>Blood</i> , 2014, 124, 4736-4736.	0.6	31
216	Phase 1B Results of Ricolinostat (ACY-1215) Combination Therapy with Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma (MM). <i>Blood</i> , 2014, 124, 4764-4764.	0.6	12

#	ARTICLE	IF	CITATIONS
217	An Integrative Network Approach for Genomic Discovery and Personalized Therapy in Relapsed Multiple Myeloma. <i>Blood</i> , 2014, 124, 3426-3426.	0.6	0
218	A phase 2 multicentre study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. <i>British Journal of Haematology</i> , 2013, 161, 357-366.	1.2	138
219	Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. <i>Haematologica</i> , 2013, 98, 1753-1761.	1.7	300
220	A Phase I Trial Of Anti-KIR Monoclonal Antibody IPH2101 and Lenalidomide For Multiple Myeloma. <i>Blood</i> , 2013, 122, 3181-3181.	0.6	3
221	Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM). <i>Blood</i> , 2013, 122, 3220-3220.	0.6	12
222	Interim Analysis Of The Mmr Commpass Trial, a Longitudinal Study In Multiple Myeloma Relating Clinical Outcomes To Genomic and Immunophenotypic Profiles. <i>Blood</i> , 2013, 122, 532-532.	0.6	34
223	A Phase II, Single-Center, Open-Label Study Of Oral Panobinostat In Combination With Lenalidomide and Weekly Dexamethasone In Patients With Multiple Myeloma. <i>Blood</i> , 2013, 122, 5392-5392.	0.6	4
224	Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients. <i>Blood</i> , 2013, 122, 758-758.	0.6	21
225	ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results Of Combination Therapy With Bortezomib In Patients With Multiple Myeloma (MM). <i>Blood</i> , 2013, 122, 759-759.	0.6	19
226	Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM): MM-002 phase II age subgroup analysis.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8532-8532.	0.8	4
227	Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8542-8542.	0.8	12
228	Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8543-8543.	0.8	10
229	Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8588-8588.	0.8	1
230	Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003). <i>Blood</i> , 2013, 122, 3185-3185.	0.6	0
231	Relationship Of Serum Free Light Chain Reduction To Best Overall Response In Phase 2 Single-Agent and Combination Studies Of Carfilzomib In Patients With Relapsed Or Relapsed and/Or Refractory Multiple Myeloma. <i>Blood</i> , 2013, 122, 1965-1965.	0.6	0
232	High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler). <i>Blood</i> , 2013, 122, 1854-1854.	0.6	0
233	Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2012, 30, 1953-1959.	0.8	273
234	A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. <i>Blood</i> , 2012, 120, 2817-2825.	0.6	608

#	ARTICLE	IF	CITATIONS
235	A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. <i>British Journal of Haematology</i> , 2012, 159, 58-66.	1.2	101
236	An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 310-318.	0.2	104
237	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	3.3	664
238	A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results. <i>Blood</i> , 2012, 120, 202-202.	0.6	16
239	Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression. <i>Blood</i> , 2012, 120, 331-331.	0.6	24
240	BT062, an Antibody-Drug Conjugate Directed Against CD138, Given Weekly for 3 Weeks in Each 4 Week Cycle: Safety and Further Evidence of Clinical Activity. <i>Blood</i> , 2012, 120, 4042-4042.	0.6	42
241	Rocilnostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study. <i>Blood</i> , 2012, 120, 4061-4061.	0.6	13
242	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure. <i>Blood</i> , 2012, 120, 4070-4070.	0.6	1
243	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis. <i>Blood</i> , 2012, 120, 450-450.	0.6	11
244	Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT).. <i>Journal of Clinical Oncology</i> , 2012, 30, 8016-8016.	0.8	11
245	A randomized phase II study of elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8020-8020.	0.8	2
246	Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8035-8035.	0.8	1
247	Stringent complete response (sCR) in patients (pts) with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX).. <i>Journal of Clinical Oncology</i> , 2012, 30, 8011-8011.	0.8	0
248	Prognostic value of post-induction β 2-microglobulin (P β 2M) in untreated multiple myeloma (MM) patients undergoing autologous stem cell transplant (ASCT).. <i>Journal of Clinical Oncology</i> , 2012, 30, e21006-e21006.	0.8	0
249	Patients with Newly Diagnosed Multiple Myeloma and a Gain of the Long Arms of Chromosome 1 Have Inferior Outcomes, Including Early Onset Extramedullary Disease, Despite the Use of Novel Triplet Regimens. <i>Blood</i> , 2012, 120, 4996-4996.	0.6	0
250	Lack of a Response by Serum Free Light Chains Performed Early Post Stem Cell Transplantation in Patients with Multiple Myeloma Predicts Inferior Progression Free and Overall Survival.. <i>Blood</i> , 2012, 120, 3127-3127.	0.6	0
251	A Phase I Trial of the Anti-Inhibitory KIR Antibody, IPH2101, and Lenalidomide in Multiple Myeloma: Interim Results. <i>Blood</i> , 2012, 120, 4058-4058.	0.6	5
252	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. <i>Blood</i> , 2011, 117, 4691-4695.	0.6	849

#	ARTICLE	IF	CITATIONS
253	International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. <i>Blood</i> , 2011, 117, 6063-6073.	0.6	282
254	Initial genome sequencing and analysis of multiple myeloma. <i>Nature</i> , 2011, 471, 467-472.	13.7	1,288
255	Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis. <i>Blood</i> , 2011, 118, 1876-1876.	0.6	13
256	A 28 Day Schedule for Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2011, 118, 2949-2949.	0.6	1
257	A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2011, 118, 303-303.	0.6	8
258	BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2011, 118, 305-305.	0.6	30
259	A Phase 2 Multicenter Study of Siltuximab, An Anti-IL-6 Monoclonal Antibody, in Patients with Relapsed or Refractory Multiple Myeloma,. <i>Blood</i> , 2011, 118, 3971-3971.	0.6	3
260	Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 631-631.	0.6	6
261	Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM. <i>Blood</i> , 2011, 118, 813-813.	0.6	4
262	Outcomes of Plasma Cell Disorder Patients with Abnormal Hepatitis B and C Screening Tests Prior to Autologous Stem Cell Harvest and Transplantation. <i>Blood</i> , 2011, 118, 4472-4472.	0.6	1
263	Unfavorable Cytogenetic Characteristics Do Not Adversely Impact Response Rates in Patients with Relapsed and/or Refractory Multiple Myeloma Treated with Single-Agent Carfilzomib on the 003 (A1) Study. <i>Blood</i> , 2011, 118, 1875-1875.	0.6	2
264	Outcomes of Salvage Autologous Stem Cell Transplant (ASCT) in Multiple Myeloma Patients Relapsed After An Initial ASCT and Refractory to Bortezomib and Immunomodulatory Agents. <i>Blood</i> , 2011, 118, 4484-4484.	0.6	0
265	The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development. <i>Blood</i> , 2011, 118, 1024-1024.	0.6	0
266	Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2010, 116, 679-686.	0.6	790
267	Cytoplasmic Immunoglobulin Fluorescence In Situ Hybridization (cIg FISH) Enhances the Quantitative Detection of Chromosome Abnormalities In Plasma Cell Neoplasms Compared to Conventional FISH. <i>Blood</i> , 2010, 116, 1198-1198.	0.6	2
268	Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase 1 Study. <i>Blood</i> , 2010, 116, 1936-1936.	0.6	2
269	Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program. <i>Blood</i> , 2010, 116, 1952-1952.	0.6	3
270	Long-Term Treatment and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM). <i>Blood</i> , 2010, 116, 1953-1953.	0.6	4

#	ARTICLE	IF	CITATIONS
271	Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (MM). Blood, 2010, 116, 1954-1954.	0.6	6
272	Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM). Blood, 2010, 116, 3031-3031.	0.6	5
273	Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up. Blood, 2010, 116, 3049-3049.	0.6	19
274	BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. Blood, 2010, 116, 3060-3060.	0.6	5
275	The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics.. Blood, 2010, 116, 3803-3803.	0.6	2
276	Carfilzomib, Lenalidomide, and Dexamethasone In Newly Diagnosed Multiple Myeloma: Initial Results of Phase I/II MMRC Trial. Blood, 2010, 116, 862-862.	0.6	5
277	Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM). Blood, 2010, 116, 985-985.	0.6	12
278	Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study. Blood, 2010, 116, 986-986.	0.6	6
279	IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody for Multiple Myeloma: Interim Phase 1 Trial Results and Correlative Biologic and Safety Data. Blood, 2010, 116, 1966-1966.	0.6	1
280	Responses and Survival Are Not Affected by Cytogenetics In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM) Treated with Single-Agent Carfilzomib. Blood, 2010, 116, 1942-1942.	0.6	2
281	A Phase II Trial of TBL 12 Sea Cucumber Extract In Patients Withuntreated Asymptomatic Myeloma. Blood, 2010, 116, 5042-5042.	0.6	1
282	Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients. Blood, 2010, 116, 1938-1938.	0.6	4
283	Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. British Journal of Haematology, 2008, 143, 537-540.	1.2	84
284	Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti-Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma. Journal of Clinical Oncology, 2008, 26, 3196-3203.	0.8	152
285	Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib. Journal of Clinical Oncology, 2006, 24, 3113-3120.	0.8	587
286	A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma. New England Journal of Medicine, 2003, 348, 2609-2617.	13.9	2,460